Safety and Efficacy of Lorlatinib (PF-06463922) in Patients with Advanced ALK+ or ROS1+Non-Small-Cell Lung Cancer (NSCLC)

被引：14

作者：

Felip, E. ^{[1
]}

Bauer, T. ^{[2
]}

Solomon, Benjamin ^{[3
]}

Besse, B. ^{[4
]}

James, L. ^{[5
]}

Clancy, J. ^{[6
]}

Klamerus, K. ^{[7
]}

Martini, J. -F. ^{[7
]}

Abbattista, A. ^{[8
]}

Shaw, A. ^{[9
]}

机构：

[1] Vall DHebron Inst Oncol, Barcelona, Spain

[2] Tennessee Oncol PLCC, Arah Cannon Canc Res Inst, Nashville, TN USA

[3] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[4] Gustave Roussy, Villejuif, France

[5] Pfizer Oncol, New York, NY USA

[6] Invent Clin, Princeton, NJ USA

[7] Pfizer Oncol, La Jolla, CA USA

[8] Pfizer Oncol, Milan, Italy

[9] Massachusetts Gen Hosp, Boston, MA 02114 USA

来源：

关键词：

ALK; ros1; non-small cell lung cancer; lorlatinib;

D O I：

10.1016/j.jtho.2016.11.433

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA07.11

引用

页码：S383 / S384

页数：2